Evidence map›Paper›PMID 19139168›Full record

ArticleThe Journal of experimental medicine2009

Runx3 and T-box proteins cooperate to establish the transcriptional program of effector CTLs.

Fernando Cruz-Guilloty, Matthew E Pipkin, Ivana M Djuretic, Ditsa Levanon, Joseph Lotem, Mathias G Lichtenheld, Yoram Groner, Anjana Rao

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of experimental medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 322 papers.

0numbers the graph read from it
0cells of the map it votes in
322citing papers in PubMed
9.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

322 citing papers in PubMed, 499 citations in OpenAlex.

  1. CD8iScience · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. AARS1-Mediated RUNX3 K193 Lactylation Enhances the Activation and Cytotoxicity of CD8Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  8. Article
  9. CD8MedComm · 2026
    Review
  10. Article
  11. Article
  12. Cytotoxic CD4Signal transduction and targeted therapy · 2026
    Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

262 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Fernando Cruz-GuillotyHarvard Medical School and the Immune Disease Institute, Boston, MA 02115, USA.
Matthew E Pipkin
Ivana M Djuretic
Ditsa Levanon
Joseph Lotem
Mathias G Lichtenheld
Yoram Groner
Anjana Rao
Harvard University · USWeizmann Institute of Science · ILSylvester Comprehensive Cancer Center · US

Funding

University of Miami Developmental Center for AIDS Research (D-CFAR)P30AI073961 · NIAID · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI ALLAN E RODRIGUEZ · 2007 to 2026
$33.8M
REGULATED ACCESSIBILITY OF A CYTOKINE GENE LOCUSR01AI044432 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI RAO, ANJANA · 1999 to 2014
$7.7M
BZIP PROTEINS AND LYMPHOCYTE GENE INDUCTIONR37CA042471 · NCI · IMMUNE DISEASE INSTITUTE, INC. · PI RAO, ANJANA · 1999 to 2006
$3.6M
ROLE OF THE FOS ONCOGENE IN LYMPHOCYTE GROWTHR01CA042471 · NCI · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI RAO, ANJANA · 1986 to 2012
$3.1M
MOLECULAR CHARACTERIZATION OF PERFORIN GENE REGULATIONR01CA055811 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI LICHTENHELD, MATHIAS GEORG · 1998 to 2001
$433k
Mechanics of LCR action on perforin to establish cytotoxicity in NK cells and CTLF32CA126247 · NCI · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI PIPKIN, MATTHEW EUGENE · 2007 to 2010
$155k
NCI NIH HHS CA42471NCI NIH HHS F32 CA126247NCI NIH HHS F32 CA126247-01NCI NIH HHS R01 CA042471NCI NIH HHS R37 CA042471NIAID NIH HHS AI44432NIAID NIH HHS P30 AI073961NIAID NIH HHS R01 AI044432
6 · The paper itself

Abstract

Activation of naive CD8(+) T cells with antigen induces their differentiation into effector cytolytic T lymphocytes (CTLs). CTLs lyse infected or aberrant target cells by exocytosis of lytic granules containing the pore-forming protein perforin and a family of proteases termed granzymes. We show that effector CTL differentiation occurs in two sequential phases in vitro, characterized by early induction of T-bet and late induction of Eomesodermin (Eomes), T-box transcription factors that regulate the early and late phases of interferon (IFN) gamma expression, respectively. In addition, we demonstrate a critical role for the transcription factor Runx3 in CTL differentiation. Runx3 regulates Eomes expression as well as expression of three cardinal markers of the effector CTL program: IFN-gamma, perforin, and granzyme B. Our data point to the existence of an elaborate transcriptional network in which Runx3 initially induces and then cooperates with T-box transcription factors to regulate gene transcription in differentiating CTLs.

Indexed as

Gene Expression RegulationAnimalsBlotting, NorthernBlotting, WesternCD8-Positive T-LymphocytesCell DifferentiationCells, CulturedCore Binding Factor Alpha 3 SubunitCytotoxicity, ImmunologicGranzymesInterferon-gammaInterleukin-2MiceMice, Inbred C57BLMice, KnockoutMice, TransgenicCore Binding Factor Alpha 3 SubunitEomes protein, mouseGranzymesInterferon-gammaInterleukin-2PerforinReceptors, Antigen, T-Cell, alpha-betaRunx3 protein, mouseT-bet Transcription FactorT-Box Domain ProteinsTumor Necrosis Factor-alpha

Identifiers

PMID19139168
PMCPMC2626671
OpenAlexW2167441884

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.